ClinicalTrials.gg
RecruitingNCT07387198NeoMatryxUpdated Nov 9, 2026

Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab

A Phase 2 interventional study of Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles and Placebo NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles. in Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II and Neoadjuvant Immunotherapy, sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. Recruiting at 12 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Nov 9, 2026Site recruiting status changed2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study is a randomized, double blind, placebo-controlled, non-comparative phase II trial that investigates the efficacy of neoadjuvant anti-PD-1 antibody Cemiplimab treatment in patients with clinical stage I or II Merkel cell carcinoma who have have undergone primary tumour excision and are pending sentinel lymph node biopsy.

02

Conditions studied

  • Merkel Cell Carcinoma, Stage I
  • Merkel Cell Carcinoma, Stage II
  • Neoadjuvant Immunotherapy

Keywords

  • merkel cell carcinoma
  • sentinel lymph node
  • PD-1 antibody
  • skin cancer
  • Cemiplimab
  • MCC
03

In context

Carcinoma, Merkel Cell

150 studies on the registry are indexed under Carcinoma, Merkel Cell; 39 are open to participants now.

This study's planned enrollment of 135 is above the median of 40 across 129 interventional studies indexed under Carcinoma, Merkel Cell.

Browse Carcinoma, Merkel Cell studies →

Lead sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest is the lead sponsor of 64 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient has signed informed written consent.
  2. Patients is 18 years and older at time of signing of written
  3. Patient has diagnosis of Merkel cell carcinoma in clinical stage II, or in stage I with minimum diameter of 1 cm, with primary tumor already removed and a planned sentinel lymph nodes still pending.
  4. Patient has performance status 0-2.
  5. Patients has adequate laboratory parameters particularly for the blood count, renal and liver function parameters.

    1. Absolute number of neutrophils ≥ 1.5 x 109/L
    2. ≥ 75 x 109/L
    3. ≥ 9 g/dL
    4. Total ≤ 1.5 times the (ULN) (patients with Gilbert´s Disease and total bilirubin up to 3x ULN may be eligible after approval from trial's medical expert)
    5. (SGOT) and ALT (SGPT) ≤ 3x ULN
    6. AP ≤ 2.5x ULN
    7. Serum creatinine ≤ 2x ULN or ≥ 40 mL/min
  6. Female patients of and male patients with female partners of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use methods that result in a failure rate of \<1% per year during the treatment period and for at least 6 months after the last dose of Cemiplimab. Male patients must refrain from donating sperm during this same period. Male patients with a pregnant partner must agree to remain abstinent or to use a condom for the duration of the pregnancy.
  7. Patient must be willing to allow translational work-up of tissue samples (PT, sentinel lymph node biopsy).

Exclusion criteria

Exclusion criteria

  1. Patient has prior sentinel lymph node removal for the current MCC.
  2. Patients received prior treatment with immunotherapy (such as /PD-L1 or CTL4) or any other systemic anti-tumor (MCC) therapy (incl. therapies)
  3. Patient has active or a history of hematological neoplasms including chronic lymphocytic leukemia (CLL), irrespective if these require treatment or not.
  4. Patient had prior organ transplantation including allogenic stem-cell transplantation.
  5. Patient receives concomitant medication, EXCEPT for the following:

    i. Intranasal, inhaled, topical , or local steroid injection (e.g., intra-articular injection).

    ii. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent.

    iii. Steroids as premedication for reactions (e.g., CT scan premedication).

  6. Patient has known hypersensitivity to any component of the Cemiplimab formulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein.
  7. Patient has active or inflammatory disorders.
  8. Patient has history of interstitial lung disease.
  9. Patient has active infection requiring systemic therapy.
  10. Patient has Active infection requiring systemic therapy, including uncontrolled , and infection or diagnosis of immunodeficiency.

    NOTE: Patients are eligible if:

    • Patients have controlled HIV infection with is > 350 cells/μL and viral load is undetectable [HIV RNA PCR]. Patients with controlled HIV infection must be monitored per local standards during the trial.
    • Patients positive for HBV surface antigen have controlled HBV infection receiving anti-viral therapy and with undetectable serum viral load [HBV DNA PCR]. Patients with controlled infection must undergo periodic monitoring of HBV DNA and p must remain on anti-viral therapy for at least 6 months after last dose of Cemiplimab.
    • Patients positive for HCV antibody have controlled HCV infection with undetectable viral load [HCV RNA PCR].
  11. Patent received vaccination with any (e.g., intranasal flu vaccine) within 4 weeks before the first dose of Cemiplimab or planned vaccination with live vaccine during the trial
  12. Female patients, who are pregnant or breast feeding or planning to become pregnant within and 6 months after the end of treatment. Female patients of must have a negative serum β-HCG pregnancy test result within 7 days prior to initiation of study treatment.
  13. Patient has evidence of any other disease, neurologic or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any of the study medications, puts the patient at higher risk for treatment-related complications or may affect the interpretation of study results.
  14. Patient has known substance abuse or other psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
  15. Patient is legally incapacitated or has limited legal capacity
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
135 participants (estimated)

Study arms

  • Experimental
    Arm A (Cemiplimab)

    2 cycles of Cemiplimab (350 mg, i.v., Q3W) followed by sentinel lymph node biopsy

    Drug: Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles

  • Placebo comparator
    Arm B (placebo)

    2 cycles of placebo followed by sentinel lymph node biopsy

    Drug: Placebo NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles.

Interventions

  • DrugCemiplimabStudies of CemiplimabCemiplimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles

    Also known as: LIBTAYO

  • DrugPlacebo NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles.

    Patients will receive NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles.

06

What researchers measure

Primary outcomes

  1. Nodal micrometastases-free rate

    rate of patients without nodal micrometastases after 2 cycles of treatment, determined by sentinel lymph node biopsy

    Time frame: up to 36 months

Secondary outcomes

  1. Recurrence-free survival

    time from randomization until date of the first of the following events: MCC recurrence, and MCC-related death

    Time frame: up to 66 months

  2. Time to recurrence

    defined as time from randomization until date of first MCC recurrence

    Time frame: up to 66 months

  3. Overall survival

    time from randomization until date of death from any cause

    Time frame: up to 66 months

  4. Quality of life using FCRI-SF questionnaire

    Quality of life determined using the FCRI-SF questionnaire

    Time frame: up to 66 months

  5. Safety (AEs and SAEs)

    incidence, nature, causality, frequency, timing and severity of adverse events using NCI CTCAE 5

    Time frame: up to 66 months

  6. Disease specific survival

    time from randomization until date of MCC-related death

    Time frame: up to 66 months

  7. Quality of life using the mFACT-M questionnaire

    Quality of life determined using the mFACT-M questionnaire

    Time frame: up to 66 months

Other outcomes

  1. Investigation of prognostic and predictive biomarkers to estimate the risk of lymph node metastases and signs of immune activation in the sentinel lymph nodes

    Biosamples will be used to determine the correlation of identified biomarkers with clinical outcome, i.e., nodal metastases-free rate, RFS, OS

    Time frame: up to 66 months

07

Study locations

11 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2029, 43 months after the start.

Of 33 phase 2 interventional studies under Carcinoma, Merkel Cell, half reached primary completion within 92 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 138. This study's planned 43 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 4, 2026
StartActual
May 29, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Jul 31, 2031
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites removed. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Universitätsklinikum Regensburg · Regensburg, GermanyNot yet recruiting→Recruiting
  • Universitätsklinikum Frankfurt · Frankfurt am Main, GermanyNot yet recruiting→Recruiting
Show 2 removed
  • Universitätsklinikum Köln · Cologne, Germany
  • Universitätsklinikum Leipzig · Leipzig, Germany
Nov 9, 2026
Secondary outcomes
1 added, 1 description edited
What changed in the outcomes
  • AddedTime to recurrenceTime frame: up to 66 months
  • DescriptionRecurrence-free survival: how it is measured was reworded
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    2 sites removed. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Universitätsklinikum Regensburg · Regensburg, GermanyNot yet recruiting→Recruiting
    • Universitätsklinikum Frankfurt · Frankfurt am Main, GermanyNot yet recruiting→Recruiting
    Show 2 removed
    • Universitätsklinikum Köln · Cologne, Germany
    • Universitätsklinikum Leipzig · Leipzig, Germany
    Secondary outcomes 1 added, 1 description edited
    What changed in the outcomes
    • AddedTime to recurrenceTime frame: up to 66 months
    • DescriptionRecurrence-free survival: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07387198
Lead sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators
Prof. Gutzmer, Skin Cancer Center Minden, Johannes-Wesling-Klinikum Minden, Germany, Universität Duisburg-Essen, Regeneron Pharmaceuticals
Responsible party
Sponsor
First posted
Feb 4, 2026
Start date
May 29, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Jul 31, 2031 (estimated)
Last update
Nov 9, 2026

Study contacts

Ralf Gutzmer, Prof. Dr. med.
Contact
Ralf.Gutzmer@Muehlenkreiskliniken.de
Michelle Tez
Contact
tez.michelle@ikf-khnw.de
Salah Al-Batran, Prof. Dr.
study director · Institut für Klinische Krebsforschung IKF GmbH
Ralf Gutzmer, Prof. Dr. med.
principal investigator · Johannes Wesling Klinikum Minden
Juergen C. Becker, Prof. Dr. Dr.
principal investigator · Translational Skin Cancer Research University Duisburg-Essen, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion